Clinical Trials Logo

Infarction clinical trials

View clinical trials related to Infarction.

Filter by:

NCT ID: NCT05986968 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

The Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage

STOP-IMH
Start date: July 6, 2023
Phase: N/A
Study type: Interventional

The main goal of this clinical trial is to assess the safety of direct omission of aspirin after Percutaneous Coronary Intervention (PCI) in patients with ST elevation myocardial infarction (STEMI). The secondary objectives are to demonstrate the reduction of intramyocardial haemorrhage and infarct size, which will be measured after 1 week; to compare clinical bleeding outcomes and to compare platelet reactivity and inflammatory response in STEMI patients receiving ticagrelor monotherapy versus dual antiplatelet therapy. Patients will be treated with either ticagrelor monotherapy or dual antiplatelet therapy (aspirin plus ticagrelor) after PCI. They will be compared to see if the omission of aspirin is safe in terms of major adverse cardiac and cerebral events at 13 months follow-up.

NCT ID: NCT05985447 Recruiting - Clinical trials for Acute Myocardial Infarction

Menopause Related Influences on Leukocyte Distribution, Monocyte Function and Platelet Reactivity

Start date: March 7, 2022
Phase:
Study type: Observational

Women and men show marked differences in cardiovascular risk profile and outcome. Women experience fewer cardiovascular events than men before menopause, but this relationship seems to reverse at menopause. These disparities are probably due to hormonal factors, especially the female sex hormone estrogen seems to have a protective influence on the development of atherosclerotic plaques premenopausal. The underlying mechanisms of the effect of estrogens on the vessel wall are still insufficiently investigated. In this study, menopause related effects on leukocyte distribution and function as well on platelets and their aggregational response will be evaluated.

NCT ID: NCT05984134 Completed - Clinical trials for Acute Myocardial Infarction

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Start date: July 15, 2022
Phase: Phase 2
Study type: Interventional

A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.

NCT ID: NCT05974930 Not yet recruiting - STEMI Clinical Trials

Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction

ULTRA-STEMI
Start date: October 1, 2023
Phase:
Study type: Observational

The main goal of the ULTRA-STEMI trial is to investigate the prognostic impact of IVUS-guided PCI in patients with STEMI and correlate IVUS measurements with clinical, procedural, imaging and follow-up outcomes of interest. Study participants will undergo primary PCI as per standardized procedures; IVUS will be performed at baseline, post-intervention and post-optimization. Manual thrombus aspiration will be performed according to clinical indications. The aspirated thrombi will be collected and scanned with micro-computed tomography (micro-CT). Also, angiographic and peri-procedural data will be gathered. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of the residual coronary-artery stenosis, if any. All patients will be followed up for at least12 months for the adjudication of major adverse cardiovascular events.

NCT ID: NCT05974397 Completed - Clinical trials for Acute Myocardial Infarction

Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan

Start date: September 30, 2021
Phase:
Study type: Observational

This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows: - A cross-sectional analysis was conducted to explore the annual incidence trends. - A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients. In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)

NCT ID: NCT05972070 Recruiting - Heart Failure Clinical Trials

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

Start date: June 1, 2023
Phase:
Study type: Observational

The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine. Several components will be assessed such as quality-of-life, nutritional counseling, maximum metabolic activity (MET's), diabetic management, tobacco cessation, lipid, blood pressure, and psychosocial management. These tasks will be accomplished through concurrent conversations between patients and their therapist's utilizing telemedicine with observed exercise training.

NCT ID: NCT05967663 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)

Start date: November 11, 2023
Phase: N/A
Study type: Interventional

It is a prospective, multicenter, randomised controlled, open-label, blinded endpoint assessment trial, to compare the strategy of immediate complete revascularisation and staged complete revascularisation in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.

NCT ID: NCT05967026 Enrolling by invitation - Clinical trials for Myocardial Infarction

Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging

MI-SCAR-MRI
Start date: July 2023
Phase:
Study type: Observational

The goal of this monocentric observationnal study is to describe the characteristics of the myocardial infarction scar in terms of transmurality in residual LVEF>35% patients. The primary objective is to determine the frequency of the criterion "intramural scar ≥1.47cm2" (measured by MRI) in patients who presented with myocardial infarction with residual LVEF≥35%.

NCT ID: NCT05966662 Recruiting - Clinical trials for Coronary Artery Disease

Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

Start date: December 8, 2023
Phase: N/A
Study type: Interventional

This investigational device exemption (IDE) study is to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System with the Shockwave C2+ 2Hz Coronary IVL Catheter to treat de novo, calcified, stenotic, coronary lesions prior to stenting.

NCT ID: NCT05955950 Enrolling by invitation - Clinical trials for Myocardial Infarction, Acute

Gratitude Intervention in Promoting Self-care in Patients With Myocardial Infarction

GReATCARE
Start date: November 5, 2022
Phase: N/A
Study type: Interventional

Introduction: Positive psychological's constructs have shown a direct effect on adherence to pharmacological treatment, diet, physical activity and general commitment to health, in the same way that negative ones, such as depression, anxiety and stress, are associated with worse cardiovascular outcomes and are prevalent in patients with infarction. Objective: To verify whether a gratitude intervention can improve self-care and improve negative psychological states in patients with recent myocardial infarction. Methods: Randomized, parallel clinical trial. The inclusion criteria will be patients with ST-segment elevation myocardial infarction (STEMI) with less than 12 hours of evolution and undergoing primary percutaneous coronary intervention (pPCI). Participants will respond to the socio-demographic and risk factors questionnaire and self-care (ASA-A), anxiety, depression and stress (DASS-21) and gratitude (QG-6) scales. They will be drawn into the gratitude intervention group or neutral events group according to the randomization list. Patients in the intervention group will be tasked with writing down 3 to 5 situations a day for which they are grateful, for 14 days. Patients in the control group will be asked to write down 3 to 5 situations a day that have impacted them, whether good or bad. Both groups will be reassessed after the intervention and after 6 months. Expected results: It is expected that the intervention group will improve self-care and the feeling of gratitude, modify behaviors and decrease negative affects, while the group without intervention will remain unchanged from the beginning of the study to 6 months.